Nathalie Lemoine1, Antoine Adenis2, Olivier Bouche3, Alain Duhamel4, Alexandra Heurgue3, Emmanuelle Leteurtre5, Eric Amela2, Julia Salleron4, Mohamed Hebbar6. 1. Department of Medical Oncology, University Hospital, Lille, France. 2. Department of Digestive Oncology, Oscar Lambret Centre, Lille, France. 3. Department of Digestive Oncology, University Hospital, Reims, France. 4. Department of Biostatistics, EA2694, University Lille Nord de France, University Hospital, Lille, France. 5. Department of Pathology, University Lille Nord de France, University Hospital, Lille, France. 6. Department of Medical Oncology, University Hospital, Lille, France mohamed.hebbar@chru-lille.fr.
Abstract
AIM: To evaluate the efficacy of first-line palliative chemotherapy, regarding the presence of signet ring cells (SRC). PATIENTS AND METHODS: Retrospective analysis of consecutive patients with locally advanced or metastatic gastric or oesogastric junction adenocarcinoma who received first-line chemotherapy. Response to chemotherapy, progression-free survival (PFS) and overall survival (OS) were compared between SRC and non-SRC (NSRC) groups. RESULTS: Two hundred and three patients were treated, with 57 (28%) having SRC adenocarcinoma. Objective response rate was significantly lower in SRC patients (5.3% vs. 28.1%, p=0.0004). PFS was not significantly different between SRC and NSRC patients (median=3.8 vs. 4.9 months, p=0.07). OS was significantly shorter in SRC patients (median=5.6 vs. 9.4 months, p<0.008). In multivariate analysis SRC was not an independent prognostic factor for OS (hazard ratio (HR)=1.28, p=0.15). CONCLUSION: Patients with advanced SRC adenocarcinomas seemed to benefit less from chemotherapy, whereas the presence of SRC was not an independent survival prognostic factor. Copyright
AIM: To evaluate the efficacy of first-line palliative chemotherapy, regarding the presence of signet ring cells (SRC). PATIENTS AND METHODS: Retrospective analysis of consecutive patients with locally advanced or metastatic gastric or oesogastric junction adenocarcinoma who received first-line chemotherapy. Response to chemotherapy, progression-free survival (PFS) and overall survival (OS) were compared between SRC and non-SRC (NSRC) groups. RESULTS: Two hundred and three patients were treated, with 57 (28%) having SRC adenocarcinoma. Objective response rate was significantly lower in SRC patients (5.3% vs. 28.1%, p=0.0004). PFS was not significantly different between SRC and NSRC patients (median=3.8 vs. 4.9 months, p=0.07). OS was significantly shorter in SRC patients (median=5.6 vs. 9.4 months, p<0.008). In multivariate analysis SRC was not an independent prognostic factor for OS (hazard ratio (HR)=1.28, p=0.15). CONCLUSION:Patients with advanced SRC adenocarcinomas seemed to benefit less from chemotherapy, whereas the presence of SRC was not an independent survival prognostic factor. Copyright
Authors: Mariana Serrano; Jhajaira M Araujo; Cristian Pacheco; Jackeline Macetas; Mariella A Blum; Alfredo Carrato; Eloy Ruiz; Francisco Berrospi; Carlos Luque; Ivan Chavez; Eduardo Payet; Luis Taxa; Paola Montenegro Journal: Ecancermedicalscience Date: 2022-05-12